Evicenter
P&T meetings

Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Regulatory submission
NDA submitted in early 2026
Launch
Not announced
Last updated
72 sources

Product information and disease descriptionPlace of product in therapyDisease description

Burden of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

23 evidence topics · 20 sources

Economic impact of SCN2A- and SCN8A-related developmental and epileptic encephalopathies on families

No evidence found.